long intergenic non-protein coding RNA 2338Genealiases: []
Q-omics provides the consensus-scored LINC02338 profile across patient tissues and cancer cell-line models. LINC02338 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC02338 is differentially expressed in 4, with the highest sampling consensus in KICH. Additionally, LINC02338 RNA expression shows 6,595 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, KICH, and STAD as cancer lineages where LINC02338 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02338 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02338 survival associations across molecular data types. LINC02338 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02338 RNA expression–survival associations across cancer types. High LINC02338 expression shows unfavorable associations in KIRC, MESO, ACC, BRCA, LGG and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC02338 RNA expression.
This table summarizes LINC02338 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02338. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02338 shows lower tumor expression in KICH, BRCA, KIRC and KIRP. The KICH box plot shows higher LINC02338 RNA expression in normal versus tumor tissue (log2 FC = −0.042, t-test p < 0.001).
This table shows molecular features associated with LINC02338 in patient tissues and cancer cell lines. In patient samples, LINC02338 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
